Description
The Defense Logistics Agency (DLA) is seeking a firm‑fixed‑price requirements contract to supply Febuxostat tablets (40 mg and 80 mg strengths, 30‑count bottles) to the DLA, VA, IHS, and Bureau of Prisons through the federal pharmaceutical Prime Vendor system. The award will be a multi‑year (base year plus up to four one‑year options) contract with a maximum performance period of five years. The solicitation uses a lowest‑price‑technically‑acceptable (LPTA) evaluation and may involve a reverse‑auction after initial evaluation.
• Quantities: ~76,388 bottles of 40 mg and ~36,627 bottles of 80 mg per year (base‑year estimate, repeated for each option year).
• Requirements: FDA cGMP‑compliant manufacturing, child‑proof packaging, specific labeling and barcode standards, and registration of product data (NDC, RxNorm, etc.) within five days post‑award.
• Financials: Firm‑fixed‑price contract with an embedded 0.5 % cost‑recovery fee; quarterly sales reporting and fee remittance required.
• Timeline: Offers open August 25 2026, final submission deadline October 29 2026 03:00 PM EST; performance to begin within 45 days of award and continue for up to five years.